Neutral
Johnson & Johnson reports durable psoriasis data; stock at $256.03.
Johnson & Johnson announced two-year data from the Phase 3 ICONIC-TOTAL study, showing that 70% of treated patients achieved clear or almost clear skin at Week 112, up from 57% at Week 16. The safety profile remained consistent over time. The stock closed at $256.03 on October 2, 2026, down 1.02% from the previous close.
Key points
- Two-year psoriasis data shows 70% of patients with clear or almost clear skin at Week 112.
- Stock closed at $256.03 on October 2, 2026, down 1.02% from the previous close.
Sources
AI-generated from public news sources. Not financial advice.
